Targeted therapy

Source: Mycosis Fungoides and Other Cutaneous T-Cell Lymphomas Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: February 19, 2025 · Captured 2026-09-09.

Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.

Context: Treatment of Stage III and Stage IV Mycosis Fungoides and Sézary Syndrome / Treatment Options for Stage III and Stage IV Mycosis Fungoides and Sézary Syndrome

Brentuximab vedotin.[50,51]

Source links and citations

Brentuximab vedotin.[50,51]

Two phase II trials of 58 patients with variable CD30 expression showed a 50% to 70% response rate with 50% of patients still in remission after 1 year.[50,51][Level of evidence C3]

Source links and citations

50
51
Level of evidence C3

Publication references

Read the original reference and check its publication notices.

PubMed 26195720 · Original source
PubMed 26261247 · Original source

Preserved source evidence · Not medical advice